Transcriptomics

Dataset Information

0

MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block


ABSTRACT: Trametinib-treated rhabdomyosarcoma cells undergo transcriptional reprogramming akin to myogenic differentiation. This reprogramming is induced by loss of ERK-mediated inhibition of MYOG expression. Restoration of MYOG allows establishment of super-enhancers at genes expressed by terminally differentiated myotubes. Our findings demonstrate that aberrant MAP kinase activity blocks differentiation in rhabdomyosarcoma and highlight trametinib as a potential therapeutic for RAS-mutated rhabdomyosarcoma.

ORGANISM(S): Homo sapiens

PROVIDER: GSE85170 | GEO | 2018/04/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-04-01 | GSE85169 | GEO
2014-12-12 | E-GEOD-64102 | biostudies-arrayexpress
2022-06-10 | GSE201138 | GEO
| PRJNA336377 | ENA
| S-EPMC8433572 | biostudies-literature
2014-12-12 | GSE64102 | GEO
2020-04-21 | GSE148994 | GEO
| PRJNA902903 | ENA
2018-03-09 | E-MTAB-6202 | biostudies-arrayexpress
2024-12-08 | GSE283634 | GEO